Cost-utility analysis of nonalcoholic steatohepatitis screening

[1]  S. Sarin,et al.  World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. , 2014, Journal of clinical gastroenterology.

[2]  J. Chen,et al.  Serum cytokeratin‐18 in the diagnosis of non‐alcoholic steatohepatitis: A meta‐analysis , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  M. Ngu,et al.  Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin‐18 fragments , 2014, Alimentary pharmacology & therapeutics.

[4]  M. Monami,et al.  Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials , 2014, Acta Diabetologica.

[5]  A. Lonardo,et al.  From NAFLD in clinical practice to answers from guidelines. , 2013, Journal of hepatology.

[6]  C. Earle,et al.  Health care costs associated with hepatocellular carcinoma: A population‐based study , 2013, Hepatology.

[7]  Ioan Sporea,et al.  Meta‐analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[8]  Carlos Vallarino,et al.  Comparing Pioglitazone to Insulin with Respect to Cancer, Cardiovascular and Bone Fracture Endpoints, Using Propensity Score Weights , 2013, Clinical Drug Investigation.

[9]  Eliseo Guallar,et al.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. , 2013, American journal of epidemiology.

[10]  Eva Herrmann,et al.  The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis , 2013, European Radiology.

[11]  H. Cortez‐Pinto,et al.  Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. , 2013, Journal of hepatology.

[12]  J. Craig,et al.  Pioglitazone and vitamin E for nonalcoholic steatohepatitis: A cost utility analysis , 2012, Hepatology.

[13]  Kevin Haynes,et al.  Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. , 2012, Journal of the National Cancer Institute.

[14]  Hui Zhu,et al.  Performance of magnetic resonance elastography and diffusion‐weighted imaging for the staging of hepatic fibrosis: A meta‐analysis , 2012, Hepatology.

[15]  D. Brenner,et al.  Correlation between liver histology and novel magnetic resonance imaging in adult patients with non‐alcoholic fatty liver disease – MRI accurately quantifies hepatic steatosis in NAFLD , 2012, Alimentary pharmacology & therapeutics.

[16]  K. Cusi,et al.  Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[17]  P. Parrilla,et al.  Detection of non-alcoholic steatohepatitis in patients with morbid obesity before bariatric surgery: preliminary evaluation with acoustic radiation force impulse imaging , 2012, European Radiology.

[18]  J. Doust,et al.  Preventing overdiagnosis: how to stop harming the healthy , 2012, BMJ : British Medical Journal.

[19]  Z. Halpern,et al.  Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. , 2012, Journal of hepatology.

[20]  M. Friedrich-Rust,et al.  Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. , 2012, European journal of radiology.

[21]  M. Lupsor,et al.  Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta‐analysis , 2012, Journal of viral hepatitis.

[22]  L. Sandrin,et al.  The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. , 2012, Clinics and research in hepatology and gastroenterology.

[23]  A. Pollett,et al.  Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients , 2012, Hepatology.

[24]  A. Webster,et al.  The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. , 2011, Journal of hepatology.

[25]  G. Musso,et al.  Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity , 2011, Annals of medicine.

[26]  S. Bertrais,et al.  Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD , 2011, European journal of gastroenterology & hepatology.

[27]  H. Sintonen,et al.  Cost of a quality‐adjusted life year in liver transplantation: The influence of the indication and the model for end‐stage liver disease score , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[28]  J. Heimbach,et al.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.

[29]  Giorgio Saracco,et al.  The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study , 2011, Hepatology.

[30]  Ned C. Rouze,et al.  Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. , 2011, Journal of hepatology.

[31]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[32]  F. Schmitt,et al.  Vitamin E and all-cause mortality: a meta-analysis. , 2011, Current aging science.

[33]  R. Ehman,et al.  Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. , 2011, Radiology.

[34]  Stavros Petrou,et al.  Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting , 2011, BMJ : British Medical Journal.

[35]  V. de Lédinghen,et al.  Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. , 2010, Ultrasound in medicine & biology.

[36]  Timothy R Card,et al.  Reduced mortality rates following elective percutaneous liver biopsies. , 2010, Gastroenterology.

[37]  Kunihiro Hosono,et al.  Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. , 2010, Radiology.

[38]  Chris Day,et al.  A position statement on NAFLD/NASH based on the EASL 2009 special conference. , 2010, Journal of hepatology.

[39]  V. de Lédinghen,et al.  Feasibility of liver transient elastography with FibroScan® using a new probe for obese patients , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[40]  Vincent Wai-Sun Wong,et al.  Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.

[41]  Laurent Castera,et al.  Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? , 2010, Gut.

[42]  Rocio Lopez,et al.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.

[43]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[44]  G. Bedogni,et al.  Epidemiology of Non-Alcoholic Fatty Liver Disease , 2010, Digestive Diseases.

[45]  S. Harrison,et al.  Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection , 2010, Hepatology.

[46]  V. de Lédinghen,et al.  Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations , 2010, Hepatology.

[47]  Greger Lindberg,et al.  Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up , 2010, Hepatology.

[48]  P. Angulo.  Long‐term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? , 2010, Hepatology.

[49]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[50]  S. Caldwell,et al.  Epidemiology and natural history of non-alcoholic steatohepatitis. , 2009, Clinics in liver disease.

[51]  A. Feldstein,et al.  Cytokeratin‐18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study , 2009, Hepatology.

[52]  K. Kowdley,et al.  Quality of life in adults with nonalcoholic fatty liver disease: Baseline data from the nonalcoholic steatohepatitis clinical research network , 2009, Hepatology.

[53]  S. Ramsey,et al.  An evaluation of the potential cost‐effectiveness of non‐invasive testing strategies in the diagnosis of significant liver fibrosis , 2009, Journal of gastroenterology and hepatology.

[54]  S. Altekruse,et al.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Chunhong Bai,et al.  Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[56]  M. Taniai,et al.  Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2009, Journal of Gastroenterology.

[57]  N. Sattar,et al.  Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. , 2008, Clinical science.

[58]  A. fong,et al.  Utilization rates, complications and costs of percutaneous liver biopsy: a population‐based study including 4275 biopsies , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[59]  P. Donnan,et al.  Health-state utilities in liver disease: a systematic review. , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[60]  P. Hewson,et al.  Surveillance of cirrhosis for hepatocellular carcinoma: a cost–utility analysis , 2008, British Journal of Cancer.

[61]  Eva Herrmann,et al.  Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. , 2008, Gastroenterology.

[62]  G. McCaughan,et al.  Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[63]  Colin P West,et al.  Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[64]  K. Schmitz,et al.  Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. , 2007, Journal of the American College of Surgeons.

[65]  Manisha Talim,et al.  Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients , 2007, Diabetes Care.

[66]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[67]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[68]  V. Foerster,et al.  Transient elastography (FibroScan) for non-invasive assessment of liver fibrosis. , 2006, Issues in emerging health technologies.

[69]  Robert A Fisher,et al.  Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C , 2006, Hepatology.

[70]  M. Manns,et al.  Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients , 2005, British Journal of Cancer.

[71]  K. Lindor,et al.  Nonalcoholic fatty liver disease , 2005, Canadian Medical Association Journal.

[72]  J. Sung,et al.  Histological progression of non‐alcoholic fatty liver disease in Chinese patients , 2005, Alimentary pharmacology & therapeutics.

[73]  Roberto Pastor-Barriuso,et al.  Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality , 2005, Annals of Internal Medicine.

[74]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[75]  E. Fassio,et al.  Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies , 2004, Hepatology.

[76]  L. Fernández-Salazar,et al.  Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. , 2004, Diabetes care.

[77]  A. McCullough,et al.  The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. , 2004, Clinics in liver disease.

[78]  James G Kench,et al.  Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C , 2003, Hepatology.

[79]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[80]  G. Naglie,et al.  Health-State Utilities and Quality of Life in Hepatitis C Patients , 2003, American Journal of Gastroenterology.

[81]  A. Detsky,et al.  Factors associated with the high cost of liver transplantation in adults. , 2002, Canadian journal of surgery. Journal canadien de chirurgie.

[82]  P. Giral,et al.  Survival, liver failure, and hepatocellular carcinoma in obesity‐related cryptogenic cirrhosis , 2002, Hepatology.

[83]  P. Angulo,et al.  Nonalcoholic fatty liver disease. , 2002, Revista de gastroenterologia de Mexico.

[84]  A. Burroughs,et al.  Assessing health‐related quality of life pre– and post–liver transplantation: A prospective multicenter study , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[85]  K. Dave,et al.  A CRITICAL APPRAISAL , 2002 .

[86]  N. Sengupta,et al.  Evaluating Quality-Adjusted Life Years , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[87]  G. Guyatt,et al.  Assessment of utilities and health-related quality of life in patients with chronic liver disease , 2001, American Journal of Gastroenterology.

[88]  M. Bennett,et al.  The natural history of nonalcoholic fatty liver: A follow‐up study , 1995, Hepatology.

[89]  S. Homan,et al.  Determining Transition Probabilities , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

[90]  I. Wanless,et al.  Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors , 1990, Hepatology.

[91]  H. Popper.  American Association for the Study of Liver Diseases: Symposium on Toxic Hepatic Injury , 1960 .

[92]  T. Poynard,et al.  Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. , 2011, Clinics and research in hepatology and gastroenterology.

[93]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[94]  N. Chalasani,et al.  Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. , 2009, Contemporary clinical trials.

[95]  G. Farrell,et al.  LIVER FAILURE AND LIVER DISEASE Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis , 2006 .

[96]  M. Camilo,et al.  Nonalcoholic steatohepatitis , 2005, Digestive Diseases and Sciences.

[97]  S. Sanderson,et al.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.

[98]  F. Askari,et al.  LIVER FAILURE AND LIVER DISEASE , 2005 .

[99]  R. Batey,et al.  Computer Assisted Quantitation of Terminal Hepatic Vein Connective Tissue in the Rat , 1992, Pathology.